Focused On-demand Library for Lymphocyte cytosolic protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q13094

UPID:

LCP2_HUMAN

Alternative names:

SH2 domain-containing leukocyte protein of 76 kDa; SLP-76 tyrosine phosphoprotein

Alternative UPACC:

Q13094; A8KA25; Q53XV4

Background:

Lymphocyte cytosolic protein 2, also known as SH2 domain-containing leukocyte protein of 76 kDa or SLP-76 tyrosine phosphoprotein, plays a crucial role in T-cell antigen receptor mediated signaling. This protein's involvement is pivotal for the proper functioning of the immune system, facilitating the communication between cells that is essential for mounting an effective immune response.

Therapeutic significance:

Immunodeficiency 81, a disorder characterized by recurrent infections and immune cell dysfunction, is directly linked to variants affecting the gene encoding Lymphocyte cytosolic protein 2. This connection underscores the protein's critical role in immune system regulation and highlights its potential as a target for therapeutic intervention in immune-related disorders.